Major Observational Study Compares Long-term Safety of Ustekinumab vs Other Biologics in IBD — 1,000+ Patient Cohort

References

1. 1.Janssen Scientific Affairs, LLC. (2020). An Observational Study to Assess the Long-term Safety of Ustekinumab Versus Other Biologic Therapies Among Patients With Crohn's Disease and Ulcerative Colitis [Clinical trial registration NCT04372108]. ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT04372108
2. 2.Feagan, B. G., Sandborn, W. J., Gasink, C., Jacobstein, D., Lang, Y., Friedman, J. R., Blank, M. A., Johanns, J., Gao, L. L., Miao, Y., Adedokun, O. J., Sands, B. E., Hanauer, S. B., Vermeire, S., Targan, S., Ghosh, S., de Villiers, W. J., Colombel, J. F., Tulassay, Z., ... UNITI–IM-UNITI Study Group. (2016). Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease. New England Journal of Medicine, 375(20), 1946-1960. https://doi.org/10.1056/NEJMoa1602773
3. 3.Ray, W. A. (2003). Evaluating medication effects outside of clinical trials: new-user designs. American Journal of Epidemiology, 158(9), 915-920. https://doi.org/10.1093/aje/kwg091
4. 4.Schneeweiss, S., & Avorn, J. (2005). A review of uses of health care utilization databases for epidemiologic research on therapeutics. Journal of Clinical Epidemiology, 58(4), 323-337. https://doi.org/10.1016/j.jclinepi.2004.10.012
5. 5.Lichtenstein, G. R., Feagan, B. G., Cohen, R. D., Salzberg, B. A., Diamond, R. H., Chen, D. M., Pritchard, M. L., & Sandborn, W. J. (2012). Serious infection and mortality in patients with Crohn's disease: more than 5 years of follow-up in the TREAT registry. American Journal of Gastroenterology, 107(9), 1409-1422. https://doi.org/10.1038/ajg.2012.18
6. 6.Sands, B. E., Sandborn, W. J., Van Assche, G., Lukas, M., Xu, J., James, A., Abhyankar, B., & Lasch, K. (2019). Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis. New England Journal of Medicine, 381(13), 1201-1214. https://doi.org/10.1056/NEJMoa1900750
7. 7.Torres, J., Bonovas, S., Doherty, G., Kucharzik, T., Gisbert, J. P., Raine, T., Adamina, M., Armuzzi, A., Bachmann, O., Bager, P., Biancone, L., Bokemeyer, B., Bossuyt, P., Burisch, J., Collins, P., El-Hussuna, A., Ellul, P., Frei-Lanter, C., Furfaro, F., ... European Crohn's and Colitis Organisation. (2020). ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment. Journal of Crohn's and Colitis, 14(1), 4-22. https://doi.org/10.1093/ecco-jcc/jjz180
8. 8.Lamb, C. A., Kennedy, N. A., Raine, T., Hendy, P. A., Smith, P. J., Limdi, J. K., Hayee, B., Lomer, M. C., Parkes, G. C., Selinger, C., Barrett, K. J., Davies, R. J., Bennett, C., Gittens, S., Dunlop, M. G., Faiz, O., Fraser, A., Garrick, V., Johnston, P. D., ... IBD Guidelines eDelphi Consensus Group. (2019). British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut, 68(Suppl 3), s1-s106. https://doi.org/10.1136/gutjnl-2019-318484